

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
22 September 2005 (22.09.2005)

PCT

(10) International Publication Number
WO 2005/087764 A1

(51) International Patent Classification⁷: **C07D 413/14**,
401/14, 403/14, A61K 31/4196, A61P 25/00

(21) International Application Number:
PCT/EP2005/002635

(22) International Filing Date: 4 March 2005 (04.03.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0405198.3 8 March 2004 (08.03.2004) GB
0414204.8 24 June 2004 (24.06.2004) GB

(71) Applicant (for all designated States except US): **GLAXO GROUP LIMITED** [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford Middlesex UB6 0NN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **ARISTA, Luca** [IT/IT]; GlaxoSmithKline, Via Alessandro Fleming 2, I-37135 Verona (IT). **BONANOMI, Giorgio** [IT/IT]; GlaxoSmithKline, Via Alessandro Fleming 2, I-37135 Verona (IT). **DAMIANI, Federica** [IT/IT]; GlaxoSmithKline, Via Alessandro Fleming 2, I-37135 Verona (IT). **HAMPRECHT, Dieter** [DE/IT]; GlaxoSmithKline, Via Alessandro Fleming 2, I-37135 Verona (IT). **MICHELLI, Fabrizio** [IT/IT]; GlaxoSmithKline, Via Alessandro Fleming 2, I-37135 Verona (IT). **TARSI, Luca** [IT/IT]; GlaxoSmithKline, Via Alessandro Fleming 2, I-37135 Verona (IT).

Verona (IT). **TEDESCO, Giovanna** [IT/IT]; GlaxoSmithKline SpA, Via Alessandro Fleming 2, I-37135 Verona (IT).

(74) Agent: **GIDDINGS, Peter, John**; GlaxoSmithKline, 980 Great West Road, Brentford Middlesex TW8 9GS (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: TETRAHYDROBENZAZEPINE DERIVATIVES AS MODULATORS OF DOPAMINE D₃ RECEPTORS (ANTIPSYCHOTIC AGENTS)



(57) Abstract: The present invention relates to novel compounds of formula (I) or a pharmaceutically acceptable salt thereof, processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as modulators of dopamine D₃ receptors, e.g. as agents to treat various aspects drug dependency or as antipsychotic agents.